SEC Form 4Coverage since Jun 26, 2026
$PRQR insider trading
Over the last 12 months, ProQR Therapeutics insiders reported 5 buys totaling $1.3M and no sales across SEC Form 4 filings.
- Bought · 12m
- $1.3M 5 events
- Sold · 12m
- — 0 events
- Events · 12m
- 5 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $PRQR · 12Mvia TradingView
Top insiders · 12m
de Boer Daniel AntonChief Executive Officer3× · $853K
Filius Bart—2× · $489K
All insider trades
5 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | de Boer Daniel AntonChief Executive Officer · O·D | ▲ Buy | 200,000 | $1.77 | $354K | +66.7% | — |
| Jul 17, 2026 | Filius BartD | ▲ Buy | 150,000 | $1.72 | $258K | +100% | — |
| Jul 9, 2026 | de Boer Daniel AntonChief Executive Officer · O·D | ▲ Buy | 150,000 | $1.74 | $261K | +100% | — |
| Jul 7, 2026 | de Boer Daniel AntonChief Executive Officer · O·D | ▲ Buy | 150,000 | $1.59 | $239K | — | — |
| Jun 26, 2026 | Filius BartD | ▲ Buy | 150,000 | $1.54 | $231K | — | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PRQR feed.